Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)
Rhea-AI Summary
Beyond Air (NASDAQ: XAIR) announced a national group purchasing agreement, effective April 1, 2026, enabling participating member hospitals and health systems to access the LungFit® PH system.
According to the company, the agreement expands commercial reach by nearly 2,000 U.S. hospitals and health systems and builds on existing GPO relationships including Vizient and Premier, increasing adoption pathways for its tankless nitric oxide solution that generates NO on demand from room air.
AI-generated analysis. Not financial advice.
Positive
- Commercial reach expanded by nearly 2,000 U.S. hospitals and health systems
- Agreement effective April 1, 2026 adds a national GPO purchasing pathway
- Now covered by purchasing agreements with three of the largest U.S. GPOs
- Tankless NO technology supports simplified workflows and reduced supply chain burden
Negative
- None.
News Market Reaction – XAIR
On the day this news was published, XAIR gained 3.48%, reflecting a moderate positive market reaction. Argus tracked a peak move of +10.7% during that session. Argus tracked a trough of -13.1% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $253K to the company's valuation, bringing the market cap to $7.52M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
XAIR was up 2.66% while scanner peers showed mixed moves: INBS up 6.43%, but CODX, SINT, and PAVM down between 5–7.51%. Broader sector dynamics exist, yet XAIR’s positive move diverges from several declining peers.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | CEO transition | Neutral | +0.2% | CEO change aiming to accelerate commercial growth for LungFit PH. |
| Mar 17 | Clinical data update | Positive | +0.3% | Early Phase 1 UNO data showing activity and favorable safety profile. |
| Mar 11 | Conference participation | Neutral | -2.6% | Company participation in the 38th Annual Roth Conference investor event. |
| Mar 10 | Deal termination | Neutral | -4.0% | Termination of planned NeuroNOS sale while exploring other strategic options. |
| Feb 20 | Scientific validation | Positive | -7.3% | Independent review highlighting antimicrobial potential of high‑dose inhaled NO. |
Recent news has often produced modest price reactions, with one notable divergence where positive scientific validation coincided with a larger selloff.
Over the last few months, Beyond Air reported multiple developments around its nitric oxide platform and LungFit PH. On Feb 20, an independent review of high‑dose iNO coincided with a -7.34% move despite supportive data. Strategic updates in March included retaining the NeuroNOS subsidiary and conference participation, with shares moving between -4.02% and -2.57%. A CEO transition on Mar 26 saw a flat reaction. Today’s GPO agreement continues the shift toward commercial execution and expanding LungFit PH access.
Regulatory & Risk Context
An effective S-3 shelf dated 2026-01-30 allows resale of existing shares and warrant shares by current investors. Beyond Air would only receive cash upon warrant exercise. The shelf has been used at least once via a 424B3 filing on 2026-02-10.
Market Pulse Summary
This announcement expands commercial access to LungFit PH by adding a new national GPO agreement effective April 1, 2026, extending reach by nearly 2,000 hospitals and building on relationships with Vizient and Premier. It reinforces a shift toward execution on LungFit PH distribution. Against a backdrop of recent financing activity, ongoing losses, and an effective S-3 shelf, investors may watch how quickly this expanded access converts into revenue and margin improvement.
Key Terms
group purchasing organization (gpo) financial
inhaled nitric oxide medical
plasma pulse technology technical
AI-generated analysis. Not financial advice.
GARDEN CITY, N.Y., April 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients’ lives, today announced it has been awarded a national group purchasing agreement for inhaled nitric oxide therapy with a leading U.S. group purchasing organization (GPO). Effective April 1, 2026, the agreement allows participating member hospitals and health systems to access the LungFit® PH system.
This new agreement builds on Beyond Air’s existing relationships with leading U.S. GPOs, including Vizient and Premier, Inc., further expanding access to a broad network of healthcare providers in the United States.
“Our GPO relationships play an important role in expanding access to LungFit PH, and this additional agreement meaningfully increases our reach by nearly 2,000 U.S. hospitals and health systems,” said Robert Goodman, Chief Executive Officer of Beyond Air. “By establishing purchasing agreements with three of the largest U.S.-based GPOs, we have created a more streamlined pathway for providers to evaluate and adopt a tankless nitric oxide solution. The endorsement of these GPOs not only expands our commercial reach, it also helps accelerate adoption as hospitals seek more efficient, cost-effective alternatives to traditional nitric oxide delivery systems.”
The LungFit PH platform utilizes patented Plasma Pulse Technology® to generate nitric oxide on demand from room air. By eliminating the need for traditional source supplies, LungFit PH supports simplified clinical workflows, reduced supply chain burden, and hospital sustainability initiatives.
This latest GPO agreement reinforces Beyond Air’s continued momentum in expanding access to LungFit PH through leading group purchasing organizations and supporting hospitals in delivering high-quality, cost-effective care.
About Beyond Air, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. For more information, visit www.beyondair.net.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the Company’s expectations related to the commercial growth, market adoption of LungFit PH, expansion in the U.S. and international markets, and the Company’s long-term strategic and financial performance. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “potential,” “will,” “would,” “could,” “may,” and similar expressions, or by the use of future tense. These statements are based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management.
Because forward-looking statements relate to future events, they are subject to inherent risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks related to the Company’s ability to successfully execute its commercial strategy, achieve market adoption of its products, maintain and expand customer relationships, manage leadership transitions effectively, obtain additional financing, and other risks described in the “Risk Factors” section of Beyond Air, Inc.’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission.
CONTACTS:
Investor Relations contact
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
(212) 915-2577
